Review on molnupiravir as a promising oral drug for the treatment of COVID-19

42Citations
Citations of this article
85Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

During the COVID-19 pandemic, various drug candidates have been developed, molnupiravir (MK-4482 and EIDD-2801), which is a new orally anti-viral agent under development for the treatment of COVID-19, is under study in the final stage of the clinical trial. Molnupiravir enhances the replication of viral RNA mutations in animals and humans. Due to the high demand for the synthesis of this drug, it was essential to develop an efficient and suitable synthetic pathway from raw material. In this study, molecular docking analysis on molnupiravir is examined also, the mechanism of action (MOA) and the recent synthetic pathway is reported. This review will be helpful to different disciplines such as medicinal chemistry, organic chemistry, biochemistry, and pharmacology. [Figure not available: see fulltext.]

Cite

CITATION STYLE

APA

Zarenezhad, E., & Marzi, M. (2022, February 1). Review on molnupiravir as a promising oral drug for the treatment of COVID-19. Medicinal Chemistry Research. Springer. https://doi.org/10.1007/s00044-021-02841-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free